U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H20N4O2
Molecular Weight 264.3235
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENTIFYLLINE

SMILES

CCCCCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O

InChI

InChIKey=MRWQRJMESRRJJB-UHFFFAOYSA-N
InChI=1S/C13H20N4O2/c1-4-5-6-7-8-17-12(18)10-11(14-9-15(10)2)16(3)13(17)19/h9H,4-8H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C13H20N4O2
Molecular Weight 264.3235
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Pentifylline is an active vasodilating substance which does not affect blood sugar levels. Pentifylline inhibits the soluble and the particulate cyclic AMP phosphodiesterases from bovine platelets and rat brain ATPase. The inhibition of ATPase by pentifylline was not influenced by the change in Na+/K+ ratio. Pentifylline in combination with Nicotinic acid indicated for the treatment of Cerebral circulatory disorders and Circulatory disorders of the eye. Pentifylline is well tolerated but it is recommended that blood pressure be monitored and if there is a severe drop in blood pressure, a drip infusion of plasma expander be administered. Coagulation states should also be closely watched.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.0 mM [IC50]
0.81 mM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
COSALDON

Approved Use

Indicated for the treatment of brain performance disorders in old age, degenerative vascular diseases in the eye.
Primary
COSALDON

Approved Use

Indicated for the treatment of brain performance disorders in old age, degenerative vascular diseases in the eye.
PubMed

PubMed

TitleDatePubMed
[Cerebral sclerosis and its treatment with cosaldon].
1957 Jun 14
[On the applicability of cosaldon in the treatment of cerebral sclerotic parkinsonism].
1959 Aug 7
[Some aspects of the pharmacological activity of a new theophylline: 1-hexyl-3, 7-dimethylxanthine (SK-7)].
1960 Jan 1
Patents

Sample Use Guides

Cerebral and peripheral circulatory disorders: 400 mg one tablet twice daily (Initial and normal dose) or 400 mg tablet daily for as long as necessary (Maintenance dose). Circulatory disorders of the eye: 400 mg two or three times daily (Initial and normal dose) or 400 mg once or twice daily for as long as necessary (Maintenance dose).
Route of Administration: Oral
In Vitro Use Guide
The secretion of type-I collagen COOH-terminal peptide (PIP) into the culture medium in the presence of pentifylline (PTF) was significantly lower than that in the presence of pentoxifylline (PTX) at concentrations of 10-1000 ug/ml; its level in cell lysate in the presence of PTX at concentrations of 10-100 ug/ml.
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:51:07 GMT 2023
Edited
by admin
on Sat Dec 16 17:51:07 GMT 2023
Record UNII
MBM1C4K26S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENTIFYLLINE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
1-HEXYLTHEOBROMINE
Systematic Name English
PENTIFYLLINE [MART.]
Common Name English
pentifylline [INN]
Common Name English
PENTIFYLLINE [MI]
Common Name English
Pentifylline [WHO-DD]
Common Name English
1-HEXYL-3,7-DIMETHYLXANTHINE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1327
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
NCI_THESAURUS C744
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
WHO-ATC C04AD01
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
WHO-VATC QC04AD01
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
Code System Code Type Description
MERCK INDEX
m8510
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID2057609
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
DRUG BANK
DB13634
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
SMS_ID
100000082514
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
EVMPD
SUB09694MIG
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
DRUG CENTRAL
2094
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
INN
3310
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
PUBCHEM
70569
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
WIKIPEDIA
PENTIFYLLINE
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
RXCUI
33086
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY RxNorm
FDA UNII
MBM1C4K26S
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
ChEMBL
CHEMBL2105338
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
NCI_THESAURUS
C66344
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
MESH
C007942
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
ECHA (EC/EINECS)
213-842-0
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
CAS
1028-33-7
Created by admin on Sat Dec 16 17:51:07 GMT 2023 , Edited by admin on Sat Dec 16 17:51:07 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY